Is Piperacillin-Tazobactam Effective for the Treatment of Pyelonephritis Caused by Extended-Spectrum β-Lactamase–Producing Organisms? | Zendy

Sima L. Sharara | Zendy; Joe Amoah | Zendy; Zoi Dorothea Pana | Zendy; Patricia J. Simner | Zendy; Sara E. Cosgrove | Zendy; Pranita D. Tamma | Zendy

Open Access

Is Piperacillin-Tazobactam Effective for the Treatment of Pyelonephritis Caused by Extended-Spectrum β-Lactamase–Producing Organisms?

Author(s) -

Sima L. Sharara,

Joe Amoah,

Zoi Dorothea Pana,

Patricia J. Simner,

Sara E. Cosgrove,

Pranita D. Tamma

Publication year - 2019

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciz1205

Subject(s) - medicine , proteus mirabilis , piperacillin/tazobactam , tazobactam , pyuria , carbapenem , odds ratio , intensive care unit , klebsiella pneumoniae , klebsiella oxytoca , piperacillin , confidence interval , propensity score matching , surgery , urine , antibiotics , imipenem , microbiology and biotechnology , pseudomonas aeruginosa , antibiotic resistance , escherichia coli , biochemistry , chemistry , genetics , bacteria , gene , biology

Limited data exist regarding the efficacy of piperacillin-tazobactam (TZP) for the management of nonbacteremic pyelonephritis caused by extended-spectrum β-lactamase (ESBL)-producing organisms.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research